We first evaluated whether HER2 transcript levels in the GHEA cohort were associated with the tumor relapse in patients who received trastuzumab‐containing adjuvant therapy, as was recently suggested (Di Modica et al., 2017). This evidence concerns the gene ERBB2 and neoplasm.